A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer

References

• International Agency for Research on Cancer (IARC), 2000.
   Google Scholar
• Ho D. Epidemiologic studies in gastric cancer. Gastric Cancer, D. Ho. Churchill Livingstone, New York 1988; 1–25
   Google Scholar
• Epelbaum R, Haim N, Stein M, Cohen Y, Robinson E. Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF). Oncology 1987; 44: 201–6
   PubMedGoogle Scholar
• Schnitzler G, Queisser W, Heim ME, Konig H, Katz R, Fritze D, et al. Phase III study of 5-FU and carmustine versus 5-FU, carmustine and doxorubicin in advanced gastric cancer. Cancer Treat Rep 1986; 70: 477–9
   PubMedGoogle Scholar
• Lopez M, Di Lauro L, Papaldo P, Conti EM. Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU. Oncology 1986; 43: 288–91
   PubMedGoogle Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
   PubMedGoogle Scholar
• Douglass HO, Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372–81
   PubMed Web of Science ®Google Scholar
• Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348–55
   PubMed Web of Science ®Google Scholar
• Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295–301
   PubMed Web of Science ®Google Scholar
• Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)- cisplatin in advanced gastric carcinoma: A phase I-II trial. Ann Oncol 2004; 15: 759–64
   PubMed Web of Science ®Google Scholar
• Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319–23
   PubMed Web of Science ®Google Scholar
• Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicentre phase II trial. Ann Oncol 2004; 15: 1204–9
   PubMed Web of Science ®Google Scholar
• Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002; 13: 1893–8
   PubMed Web of Science ®Google Scholar
• Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207–12
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543–8
   PubMed Web of Science ®Google Scholar
• Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453–8
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57
   PubMed Web of Science ®Google Scholar
• Findlay M, Hill A, Cunningham D, Norman A, Nicolson M, Ford H, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609–16
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996–2004
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infu sional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644–9
   PubMed Web of Science ®Google Scholar
• Ducreaux, M, Bouche, O, Pignon, JP, Raoul, JL, Mousseau, M, Deguiral, P, et al. Randomized trial comparing three different schedules of infusional 5FU and raltitrexed alone in first line metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive 9601 trial. Ann Oncol 2002;13:71, (abstr 259).
   Google Scholar
• Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671–8
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003; 42: 832–6
   PubMed Web of Science ®Google Scholar
• Moiseyenko, VM, Ajani, J, Tjulandin, SA, Majlis, A, Constenla, M, Boni, C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 2005;23:308s. (abstr 4002).
   Google Scholar
• Dank, M, Zaluski, J, Barone, C, Valvere, V, Peschel, C, Wenczl, M, et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005;23:308s. (abstr 4003).
   Google Scholar